市場調查報告書

全球肺炎球菌疫苗市場:成長,趨勢,及預測

Pneumococcal Vaccines Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 922056
出版日期 內容資訊 英文 111 Pages
商品交期: 2-3個工作天內
價格
全球肺炎球菌疫苗市場:成長,趨勢,及預測 Pneumococcal Vaccines Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年01月01日內容資訊: 英文 111 Pages
簡介

本報告提供全球肺炎球菌疫苗市場的相關調查,市場機會和趨勢,成長及阻礙因素,各疫苗類型、產品類型、流通管道、地區的市場分析,競爭情形,主要企業的簡介等資訊。

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 肺炎疫苗接種計劃相關政府的意識提升計劃
    • 肺炎球菌造成的污染增加
    • 新肺炎球菌疫苗的介紹
  • 市場阻礙因素
    • 生產期間長
    • 高的生產成本
  • 波特的五力分析

第5章 市場區隔

  • 各疫苗類型
    • 肺炎球菌混合疫苗
    • 肺炎球菌多糖疫苗
  • 各產品類型
    • Prevnar
    • Synflorix
    • Pneumovax23
  • 各流通管道
    • 流通聯盟企業
    • 非官方機構
    • 政府
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • GlaxoSmithKline plc
    • Pfizer Inc.
    • Merck & Co., Inc
    • Serum Institute of India Pvt. Ltd.
    • CSL Ltd.
    • Sanofi Pasteur Inc

第7章 市場機會及今後趨勢

目錄
Product Code: 67711

Market Overview

The pneumococcal vaccines market studied was projected to grow with a CAGR of nearly 7.5% over the forecast period. The major factor attributing to the growth of the market increasing the prevalence of pneumococcal contaminations. According to National Center for Immunization and Respiratory Diseases, each year in the United States, more than 250,000 people are hospitalized due to pneumonia and about 50,000 people die from the disease each year in the United States. Furthermore, the growing awareness programs initiated by the government are also boosting the market growth. Rising production of novel vaccines is also another major factor for market growth. However, the high cost involved in the production of vaccines, and the long duration for the process of production are the major drawbacks for market growth.

Scope of the Report

As per the scope of the report, Pneumonia is a type of acute respiratory illness that affects the lungs, in which the alveoli are filled with pus and fluid, which makes breathing painful and limits oxygen intake. This report is segmented by Vaccine Type, by Product Type, by Distribution Channel, and by Geography.

Key Market Trends

Pneumococcal conjugate vaccine segment expected to dominate throughout the forecast period.

  • A conjugate vaccine is a substance that is comprised of a polysaccharide antigen fused to a carrier molecule. This improves the stability and efficacy of the vaccine.
  • The Pneumococcal conjugate vaccine segment is a major contributor to the global pneumonia vaccine market, this is credited to the wide age group that is covered by this type of vaccine. These vaccines can vaccinate infants and children from 6 weeks to 5 years of age to prevent pneumonia and acute otitis media.
  • Furthermore, the conjugate vaccine stimulates immunological memory and reduces asymptomatic delivery of the bacteria, resulting in marked group immunity. Thus this segment has a higher market share.

North America Dominates the Market and Asia Pacific is expected to grow at a higher CAGR in the Forecast Period

North America is expected to dominate the overall market, throughout the forecast period. Factors such as the presence of key players and established healthcare infrastructure are the key factors accountable for its large share in the market. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase the market growth. The Asia Pacific is the fastest-growing region due to the high prevalence of pneumococcal infection. The major countries of this region have the highest-burden in the world and hence there is more need for vaccination to prevent the disease.

Competitive Landscape

The pneumococcal vaccine market is highly consolidated and consists of a few players. Some of the companies which are currently dominating the market are GlaxoSmithKline plc, Pfizer Inc., CSL Ltd., Merck & Co., Inc., Serum Institute of India Pvt. Ltd., Sanofi Pasteur Inc.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing government awareness programs regarding pneumonia immunization program
    • 4.2.2 Rising prevalence of pneumococcal contaminations
    • 4.2.3 Introduction of novel pneumococcal vaccines
  • 4.3 Market Restraints
    • 4.3.1 Long duration for the production
    • 4.3.2 High cost of production
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Vaccine Type
    • 5.1.1 Pneumococcal conjugate vaccine
    • 5.1.2 Pneumococcal polysaccharide vaccine
  • 5.2 By Product Type
    • 5.2.1 Prevnar 13
    • 5.2.2 Synflorix
    • 5.2.3 Pneumovax23
  • 5.3 By Distribution Channel
    • 5.3.1 Distribution partner companies
    • 5.3.2 Non-governmental Organizations
    • 5.3.3 Government Authorities
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 GlaxoSmithKline plc
    • 6.1.2 Pfizer Inc.
    • 6.1.3 Merck & Co., Inc
    • 6.1.4 Serum Institute of India Pvt. Ltd.
    • 6.1.5 CSL Ltd.
    • 6.1.6 Sanofi Pasteur Inc

7 MARKET OPPORTUNITIES AND FUTURE TRENDS